Alvotech (ALVO) Non-Current Deffered Revenue (2021 - 2025)
Alvotech (ALVO) posted Non-Current Deffered Revenue of $5.5 million for Q4 2025, down 93.19% on a QoQ basis from $80.7 million in Q4 2024, and down 93.19% year-over-year from $80.7 million in Q4 2024.
Alvotech (ALVO) Non-Current Deffered Revenue (2021 - 2025) Analysis & Trends
Alvotech's Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $5.5 million for Q4 2025.
- Quarterly Non-Current Deffered Revenue fell 93.19% year-over-year to $5.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.5 million (down 93.19% YoY) and the FY2025 annual result came in at $5.5 million, down 93.19% from the prior year.
- Non-Current Deffered Revenue was $5.5 million for Q4 2025 at Alvotech, down from $80.7 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $80.7 million in Q4 2024 and bottomed at $5.5 million in Q4 2025.
- A 5-year average of $52.3 million and a median of $57.0 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue gained 28.49% — and 2025, when it tumbled 93.19%.
- Alvotech's Non-Current Deffered Revenue stood at $44.8 million in 2021, then rose by 27.15% to $57.0 million in 2022, then climbed by 28.49% to $73.3 million in 2023, then advanced by 10.18% to $80.7 million in 2024, then tumbled by 93.19% to $5.5 million in 2025.
- Business Quant data shows ALVO's Non-Current Deffered Revenue at $5.5 million in Q4 2025, $80.7 million in Q4 2024, and $73.3 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Alvotech | 935.87 Mn | 935.87 Mn | 5.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.50 Mn |
| Dec 31, 2024 | 80.72 Mn |
| Dec 31, 2023 | 73.26 Mn |
| Dec 31, 2022 | 57.02 Mn |
| Dec 31, 2021 | 44.84 Mn |